About BellBrook Labs
Founded more than 20 years ago, BellBrook Labs develops biochemical assay technologies, validated enzymes and high-throughput screening (HTS) tools that support drug discovery and enzyme research. The company specialises in protein biochemistry and enzymology, providing assay platforms that enable sensitive measurement of enzyme activity and cellular signalling pathways. Its technologies support applications across kinase, ATPase, GTPase, methyltransferase, helicase, phosphodiesterase and innate immune pathway research, helping scientists generate reproducible data for target validation, compound screening and lead optimisation studies.
BellBrook Labs’ portfolio includes the proprietary Transcreener®, AptaFluor® and Enzolution™ platforms, together with validated enzymes, substrates, assay reagents, buffers and workflow protocols. These technologies are designed for compatibility with automated screening environments and standard multimode plate readers, supporting a range of pharmaceutical, biotechnology and academic research workflows. In addition to assay reagents, the company provides assay development, validation and optimisation expertise to improve experimental performance and data quality.
Europa Biosite subsidiaries distribute BellBrook Labs products in Austria, Belgium, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Sweden, Switzerland and the United Kingdom.